Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

tes from discovery into the clinic."

Principal investigator Osama Gaber, M.D., F.A.C.S. Director, Transplant Center of Excellence at The Methodist Hospital, Houston, Texas said, "Our clinical team is excited to participate in clinical trials that evaluate new therapies for renal transplant patients. Patients that develop DGF following renal transplantation have inferior kidney graft survival compared to those who do not. There is a real unmet medical need for a drug product to prevent DGF."

Daniel Zurr, Chief Executive Officer, commented, "We are very pleased to announce initiation of human dosing of the systemically administered QPI-1002 in our Phase I/II trial in kidney transplant patients. Furthermore, our siRNA drug candidate, PF-4523655, has been advanced into two Phase II clinical trials -- one for diabetic macular edema and the other for age related macular degeneration -- by our licensee, Pfizer. In addition, we recently announced that our QPI-1007 drug candidate, utilizing a novel siRNA structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. These significant developments confirm the robustness of Quark's clinical pipeline and the strength of its capabilities in the RNAi arena."

Delayed graft function (DGF) is one of the most common complications during the immediate postoperative period in renal transplantation and affects 25-40% of the deceased donor renal transplants in the United States. DGF in renal transplantation results most often from ischemia-reperfusion injury that occurs when the blood flow is re-established to the transplanted kidney initiating a chain of events that can lead to severe renal damage upon transplantation. Post-kidney transplant DGF is associated with longer hospital stays and higher rates of graft rejection, which in turn decreases the survival of the transplanted kidney (graft survival). Current
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... YORK , Dec. 17, 2014 ... imaging (MRI), the MRI market is seeing new ... and breast MRI scans account for the majority ... a higher resolution of images, which are creating opportunities ... imaging (MRI) market is growing at a rate ...
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)... BUENA, N.J. , Dec. 17, 2014  IGI ... announced today the closing of its offering of $125 ... due 2019 (the "Notes").  The Notes were offered and ... 144A under the Securities Act of 1933, as amended ... at a fixed rate of 3.75% per year, payable ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... , Rochester Medical Corporation (Nasdaq: ROCM ) will ... 2009. The Company will then hold a quarterly conference call ... 3:30 p.m. central time (4:30 p.m. eastern time). , This call ... Medical,s website at www.rocm.com . To listen ...
... Oct. 28 Qualsec (OTC Bulletin Board: QLSZ), which recently ... has been elected as a member of the Board of ... of clinical experience followed by 6 years of medical device ... and only FDA cleared RFID medical information device of its ...
Cached Medicine Technology:Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009 2VitaminSpice Appoints Dr. Richard F. Seelig as Director 2
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Greater participation ... new study finds. Researchers followed kids in the ... to poor children in Los Angeles. Over two ... larger improvements in how the brain processes speech and ... Also, the benefits of active participation in music ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... work commitment is a big reason why, new research suggests. ... Mathias Basner, an assistant professor of sleep and chronobiology in ... A time-use survey of nearly 125,000 Americans, ages 15 ... exchanged for sleep. Short sleepers -- those who slept six ...
(Date:12/15/2014)... December 15, 2014 Veretekk.com, Inc. announced ... Ocean Avenue. JM Ocean Avenue has secured exclusive ... online automated marketing system. JM Ocean Avenue is ... merger of Ocean Avenue and JM International, with partial ... Billion per year company. , “After nearly 2 decades ...
(Date:12/15/2014)... SIMpalm, a leading mobile app development company , ... client, which allows users to keep track of wines ... the right wine. At the center of WineMatch ... and wine information. All this information is assembled to ... that are close counterparts to one another are called ...
(Date:12/15/2014)... Steven Reinberg HealthDay Reporter ... study should reassure the millions of American women who have ... cancer. "There is no association between migraine and breast ... of medicine at Harvard Medical School. "There is no positive ... is no protective effect either." About 18 percent of ...
Breaking Medicine News(10 mins):Health News:Music Classes Boost Language Skills, Study Says 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2
... Web Site Strategy and Design, NEW YORK, ... been selected to develop a new web site ... of Public Health, one of the world,s,leading research, ... public health issues., "The Mailman website provides ...
... the,release of a new slimmer and more streamlined SenseWear(R) ... is 40% smaller than the previous model and weighs ... ergonomic,design intended to provide improved comfort and can be ... little device that could have a huge impact on,behavior ...
... Detroit bring up the rear, survey says , , MONDAY, May ... hearts in tip-top shape face the fewest challenges in Minneapolis, ... the list of the 10 most heart-healthy U.S. metropolitan areas ... But the list, released Monday by the American Heart Association, ...
... unnecessary surgeries , , MONDAY, May 19 (HealthDay News) ... lectin molecule called galectin-3 could help improve identification of ... surgeries, according to an Italian study. , The ... is to examine cells extracted by fine-needle aspiration. About ...
... survey says , , MONDAY, May 19 (HealthDay News) -- Women ... the fewest challenges in Minneapolis, Washington, D.C., and San Francisco. ... most heart-healthy U.S. metropolitan areas for women, a list that,s ... by the American Heart Association, also found the 10 metropolitan ...
... Disease Awareness Levels, However, ... More Doctor Visits Are Still Needed -, ... three,years, Hispanic-Americans have become increasingly aware of a potentially,serious ... Reflux Disease. Approximately 6.1 million Hispanics in the United,States ...
Cached Medicine News:Health News:Format-Studio Selected by Columbia University Mailman School of Public Health 2Health News:BodyMedia Releases New & Improved SenseWear(R) WMS Armband 2Health News:Minneapolis Tops List of Heart-Friendly Cities for Women 2Health News:Minneapolis Tops List of Heart-Friendly Cities for Women 3Health News:Protein Helps ID Thyroid Cancer Nodules 2Health News:Minneapolis Tops List of Heart-Healthy Cities for Women 2Health News:Minneapolis Tops List of Heart-Healthy Cities for Women 3Health News:New Survey Reveals Hispanic-Americans Are Taking Steps to Better Understand and Manage GERD 2Health News:New Survey Reveals Hispanic-Americans Are Taking Steps to Better Understand and Manage GERD 3Health News:New Survey Reveals Hispanic-Americans Are Taking Steps to Better Understand and Manage GERD 4Health News:New Survey Reveals Hispanic-Americans Are Taking Steps to Better Understand and Manage GERD 5
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Duckbill type sharp. 3 mm wide x 8 mm long curved blade. Octagonal handle....
9 mm slightly curved blade. Hexagonal handle....
Medicine Products: